Virolab, Inc. - FORM 10-Q/A - XML - IDEA: XBRL DOCUMENT - November 15, 2012

Attached files
FileFilename
EXCEL - IDEA: XBRL DOCUMENT - Virolab, Inc.Financial_Report.xls
XML - IDEA: XBRL DOCUMENT - Virolab, Inc.R6.htm
XML - IDEA: XBRL DOCUMENT - Virolab, Inc.R2.htm
XML - IDEA: XBRL DOCUMENT - Virolab, Inc.R1.htm
XML - IDEA: XBRL DOCUMENT - Virolab, Inc.R4.htm
XML - IDEA: XBRL DOCUMENT - Virolab, Inc.R9.htm
XML - IDEA: XBRL DOCUMENT - Virolab, Inc.R8.htm
XML - IDEA: XBRL DOCUMENT - Virolab, Inc.R5.htm
XML - IDEA: XBRL DOCUMENT - Virolab, Inc.R3.htm
XML - IDEA: XBRL DOCUMENT - Virolab, Inc.R12.htm
XML - IDEA: XBRL DOCUMENT - Virolab, Inc.R13.htm
XML - IDEA: XBRL DOCUMENT - Virolab, Inc.R14.htm
XML - IDEA: XBRL DOCUMENT - Virolab, Inc.R11.htm
XML - IDEA: XBRL DOCUMENT - Virolab, Inc.R16.htm
XML - IDEA: XBRL DOCUMENT - Virolab, Inc.R15.htm
XML - IDEA: XBRL DOCUMENT - Virolab, Inc.R10.htm
10-Q/A - AMENDMENT NO. 1 TO QUARTERLY REPORT TO ADD XBRL - Virolab, Inc.viro10qa6302012.htm
v2.4.0.6
Background Information
 3 Months Ended
Jun. 30, 2012
Notes to Financial Statements  
Background information

1. Background Information

 

Virolab, Inc. (“the Company”) was incorporated in the state of Delaware on May 4, 2010 under the name Accelerated Acquisitions X, Inc. The Company was formed as a “shell company” with no operations while it sought new business opportunities.  On March 8, 2011, we entered into a   Licensing Agreement,   pursuant to which the Company received an exclusive, non-transferrable worldwide license to specified technology, patents, intellectual property, know-how, trade secret information, clinical trial protocols and data, as well as commercial rights to:

 

·   an investigational therapeutic vaccine for the human papillomavirus (“HPV”) and HPV-related cancers and
·   a diagnostic blood test for HPV.

 

As a result of entering into the licensing agreement and undertaking efforts into the research and development its product candidates, the Company ceased to be a shell company. The Company changed its name to Virolab, Inc. on April 5, 2011. The Company operates in one reportable business segment, the development and commercialization of products to improve human healthcare.

 

The Company is currently in the development stage. All activities of the Company to date relate to its organization and acquiring rights to its product candidates. None of the Company’s product candidates have been approved for sale in any countries.

User Contributions:

Comment about this document or add new information about this topic:

CAPTCHA


This web site and associated pages are not associated with, endorsed by, or sponsored by Virolab, Inc. and has no official or unofficial affiliation with Virolab, Inc.


Based on public records. Inadvertent errors are possible.
Faqs.org does not guarantee the accuracy or timeliness of any information on this site.  Use at your own risk. This website is not associated with the SEC

Some parts © 2013 Advameg, Inc.